Compare Stocks: HEPA, MDCX, ADXN, and CVKD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXN Addex Therapeutics	$2.90 -3.8%	$3.92	$2.56 ▼ $11.97	$3.71M	1.52	15,300 shs	5,192 shs
CVKD Cadrenal Therapeutics	$1.02 +2.3%	$1.33	$0.82 ▼ $14.35	$3.56M	1.93	210,363 shs	344,292 shs
HEPA Hepion Pharmaceuticals	$0.09 +49.5%	$0.08	$0.03 ▼ $0.13	$1.04M	1.52	26,706 shs	10,365 shs
MDCX Medicus Pharma	$3.12 -4.9%	$10.12	$2.92 ▼ $139.00	$4.14M	0.3	94,743 shs	68,010 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXN Addex Therapeutics	-6.16%	-7.66%	-15.92%	-54.39%	-66.02%
CVKD Cadrenal Therapeutics	+2.31%	+4.91%	-3.77%	-56.22%	-92.77%
HEPA Hepion Pharmaceuticals	+49.51%	-24.00%	+15.44%	+64.32%	+41.61%
MDCX Medicus Pharma	-4.88%	-61.05%	-60.83%	-84.63%	-97.38%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXN Addex Therapeutics	$2.90 -3.8%	$3.92	$2.56 ▼ $11.97	$3.71M	1.52	15,300 shs	5,192 shs
CVKD Cadrenal Therapeutics	$1.02 +2.3%	$1.33	$0.82 ▼ $14.35	$3.56M	1.93	210,363 shs	344,292 shs
HEPA Hepion Pharmaceuticals	$0.09 +49.5%	$0.08	$0.03 ▼ $0.13	$1.04M	1.52	26,706 shs	10,365 shs
MDCX Medicus Pharma	$3.12 -4.9%	$10.12	$2.92 ▼ $139.00	$4.14M	0.3	94,743 shs	68,010 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXN Addex Therapeutics	-6.16%	-7.66%	-15.92%	-54.39%	-66.02%
CVKD Cadrenal Therapeutics	+2.31%	+4.91%	-3.77%	-56.22%	-92.77%
HEPA Hepion Pharmaceuticals	+49.51%	-24.00%	+15.44%	+64.32%	+41.61%
MDCX Medicus Pharma	-4.88%	-61.05%	-60.83%	-84.63%	-97.38%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADXN Addex Therapeutics	1.00	Sell	N/A	N/A
CVKD Cadrenal Therapeutics	2.00	Hold	$13.00	1,174.51% Upside
HEPA Hepion Pharmaceuticals	0.00	N/A	N/A	N/A
MDCX Medicus Pharma	2.50	Moderate Buy	$450.00	14,323.08% Upside

Current Analyst Ratings Breakdown

Latest HEPA, MDCX, ADXN, and CVKD Analyst Ratings

Date	Company	Brokerage	Action	Rating
10/2/2026	ADXN Addex Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
10/2/2026	MDCX Medicus Pharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/14/2026	MDCX Medicus Pharma	Alliance Global Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/17/2026	MDCX Medicus Pharma	Alliance Global Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
7/28/2026	MDCX Medicus Pharma	Alliance Global Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy
7/17/2026	CVKD Cadrenal Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADXN Addex Therapeutics	$210K	16.96	N/A	N/A	$4.67 per share	0.62
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	$1.17 per share	N/A
HEPA Hepion Pharmaceuticals	N/A	N/A	N/A	N/A	$1.29 per share	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	$0.07 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADXN Addex Therapeutics	-$8.12M	-$5.94	N/A	N/A	N/A	N/A	-174.44%	-126.47%	11/9/2026 (Estimated)
CVKD Cadrenal Therapeutics	-$13.24M	-$4.90	N/A	N/A	N/A	N/A	-406.41%	-273.80%	11/9/2026 (Estimated)
HEPA Hepion Pharmaceuticals	-$48.93M	-$72.15	N/A	N/A	N/A	N/A	-812.56%	-207.31%	N/A
MDCX Medicus Pharma	-$35.46M	-$2.46	N/A	N/A	N/A	N/A	-3,137.84%	-263.24%	11/13/2026 (Estimated)

Latest HEPA, MDCX, ADXN, and CVKD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	CVKD Cadrenal Therapeutics	-$0.91	N/A	N/A	N/A	N/A	N/A
9/25/2026	Q2 2026	ADXN Addex Therapeutics	N/A	-$1.48	N/A	-$1.48	N/A	$0.01 million
8/13/2026	Q2 2026	CVKD Cadrenal Therapeutics	-$1.42	-$1.14	+$0.28	-$1.14	N/A	N/A
8/13/2026	Q2 2026	HEPA Hepion Pharmaceuticals	-$200.00	-$0.08	+$199.92	N/A	N/A	N/A
8/12/2026	Q2 2026	MDCX Medicus Pharma	-$6.3750	-$10.50	-$4.1250	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADXN Addex Therapeutics	N/A	N/A	N/A	N/A	N/A
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	N/A
HEPA Hepion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADXN Addex Therapeutics	N/A	0.76	0.76
CVKD Cadrenal Therapeutics	N/A	3.73	3.73
HEPA Hepion Pharmaceuticals	N/A	1.30	1.30
MDCX Medicus Pharma	N/A	1.57	1.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADXN Addex Therapeutics	16.14%
CVKD Cadrenal Therapeutics	7.92%
HEPA Hepion Pharmaceuticals	17.24%
MDCX Medicus Pharma	N/A

Insider Ownership

Company	Insider Ownership
ADXN Addex Therapeutics	15.00%
CVKD Cadrenal Therapeutics	14.59%
HEPA Hepion Pharmaceuticals	0.06%
MDCX Medicus Pharma	8.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADXN Addex Therapeutics	3	1.23 million	1.05 million	Not Optionable
CVKD Cadrenal Therapeutics	5	3.57 million	3.05 million	Not Optionable
HEPA Hepion Pharmaceuticals	20	11.44 million	6.63 million	No Data
MDCX Medicus Pharma	16	1.26 million	1.16 million	N/A

HEPA, MDCX, ADXN, and CVKD Headlines

Recent News About These Companies

Medicus Charts Multi-Asset Growth Strategy After Three Years Of Expansion; Stock Down

October 8, 2026 | rttnews.com

Medicus Pharma Outlines Clinical Development Strategy Across Three Drug Programs Following $90 Million in Financing

October 8, 2026 | finance.yahoo.com

Medicus Pharma targets partnerships and clinical milestones as oncology pipeline advances

October 8, 2026 | proactiveinvestors.com

Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value

October 8, 2026 | globenewswire.com

Medicus Pharma announces major share consolidation plan

October 7, 2026 | tipranks.com

Medicus Pharma seeks FDA alignment on streamlined Phase 2b/3 Teverelix study

October 5, 2026 | finance.yahoo.com

Medicus Pharma Files Phase 2b/3 Trial Design For Teverelix

September 29, 2026 | rttnews.com

Medicus Pharma Advances Teverelix Into Streamlined Phase 2b/3 Design

September 29, 2026 | rttnews.com

Medicus Pharma files streamlined Phase 2b/3 prostate cancer trial design with FDA

September 29, 2026 | proactiveinvestors.com

Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer

September 29, 2026 | globenewswire.com

Medicus Pharma Narrows SkinJect Focus To Gorlin Syndrome, Drops Sporadic BCC Program

September 22, 2026 | rttnews.com

Medicus Pharma to focus SkinJect development exclusively on Gorlin syndrome patients

September 21, 2026 | proactiveinvestors.com

Medicus Pharma Narrows SkinJect Development to Gorlin Syndrome in Capital-Efficient Shift

September 21, 2026 | tipranks.com

Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment

September 21, 2026 | markets.businessinsider.com

Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment

September 21, 2026 | globenewswire.com

Analysts Are Bullish on These Healthcare Stocks: Genmab (GMAB), Medicus Pharma Ltd (MDCX)

September 15, 2026 | theglobeandmail.com

Medicus Pharma Ends Standby Equity Purchase Agreement

September 14, 2026 | tipranks.com

Analysts Offer Insights on Healthcare Companies: Medicus Pharma Ltd (MDCX) and Labcorp Holdings (LH)

September 12, 2026 | theglobeandmail.com

Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI

September 12, 2026 | proactiveinvestors.com

Medicus Pharma Announces Equity-Based Bonus Share Issuance

September 11, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HEPA, MDCX, ADXN, and CVKD Company Descriptions

Addex Therapeutics NASDAQ:ADXN

$2.90 -0.12 (-3.82%)

Closing price 10/14/2026 01:57 PM Eastern

Extended Trading

$2.98 +0.09 (+2.94%)

As of 04:22 AM Eastern

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Cadrenal Therapeutics NASDAQ:CVKD

$1.02 +0.02 (+2.31%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$0.99 -0.03 (-2.94%)

As of 04:17 AM Eastern

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Hepion Pharmaceuticals NASDAQ:HEPA

$0.09 +0.03 (+49.51%)

As of 10/14/2026 01:53 PM Eastern

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Medicus Pharma NASDAQ:MDCX

$3.12 -0.16 (-4.88%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$2.91 -0.21 (-6.73%)

As of 04:18 AM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HEPA, MDCX, ADXN, and CVKD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HEPA, MDCX, ADXN, and CVKD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HEPA, MDCX, ADXN, and CVKD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HEPA, MDCX, ADXN, and CVKD Company Descriptions

Addex Therapeutics NASDAQ:ADXN

Cadrenal Therapeutics NASDAQ:CVKD

Hepion Pharmaceuticals NASDAQ:HEPA

Medicus Pharma NASDAQ:MDCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HEPA, MDCX, ADXN, and CVKD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HEPA, MDCX, ADXN, and CVKD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HEPA, MDCX, ADXN, and CVKD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HEPA, MDCX, ADXN, and CVKD Company Descriptions

Addex Therapeutics NASDAQ:ADXN

Cadrenal Therapeutics NASDAQ:CVKD

Hepion Pharmaceuticals NASDAQ:HEPA

Medicus Pharma NASDAQ:MDCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools